Teva’s new royalty deal; Selecta merges with Cartesian; Vir’s hepatitis datanews2023-11-13T16:00:53+00:00November 13th, 2023|Endpoints News|
Legend and Novartis sign $100M deal for next CAR-T betsnews2023-11-13T15:53:28+00:00November 13th, 2023|Endpoints News|
Ajinomoto to buy gene therapy CDMO Forge Biologics in $620M all-cash dealnews2023-11-13T15:29:13+00:00November 13th, 2023|Endpoints News|
VectorY raises $138M Series A to bring its vectorized antibody for ALS into the clinic in 2025news2023-11-13T14:30:56+00:00November 13th, 2023|Endpoints News|
Aclaris loses 85% of share value after another PhII setback in inflammatory conditionnews2023-11-13T13:58:59+00:00November 13th, 2023|Endpoints News|
UCB, Eli Lilly-backed ViaNautis raises $25M in Series A to develop genetic nanomedicinesnews2023-11-13T10:07:56+00:00November 13th, 2023|Endpoints News|
Alnylam’s longer-term RNAi treatment lowers blood pressure in mid-stage studynews2023-11-13T09:27:34+00:00November 13th, 2023|Endpoints News|
Verve shares first base editing results in patients with HeFHnews2023-11-12T20:30:10+00:00November 12th, 2023|Endpoints News|
First data for Lilly’s RNA treatment for heart disease point to long-term durability in tiny group of patientsnews2023-11-12T09:33:13+00:00November 12th, 2023|Endpoints News|
Trial of Wegovy’s cardiovascular benefits shows new details behind 20% risk reductionnews2023-11-11T13:30:42+00:00November 11th, 2023|Endpoints News|
